Association between caffeine intake and age at onset in Huntington's disease
Habitual consumption of caffeine, a non-selective adenosine receptor (AR) antagonist, has been suggested to be beneficial in Parkinson's and Alzheimer's diseases. Experimental evidence support that ARs play a role in Huntington's disease (HD) raising the hypothesis that caffeine may b...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2013-10-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996113001551 |
id |
doaj-c66d747e16594f4389dca9b322499c97 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Clémence Simonin Cécile Duru Julia Salleron Pascale Hincker Perrine Charles Arnaud Delval Katia Youssov Sylvie Burnouf Jean-Philippe Azulay Christophe Verny Clarisse Scherer Christine Tranchant Cyril Goizet Sabrina Debruxelles Luc Defebvre Bernard Sablonnière Monique Romon-Rousseaux Luc Buée Alain Destée Olivier Godefroy Alexandra Dürr Bernhard Landwehrmeyer Anne-Catherine Bachoud-Levi Florence Richard David Blum Pierre Krystkowiak |
spellingShingle |
Clémence Simonin Cécile Duru Julia Salleron Pascale Hincker Perrine Charles Arnaud Delval Katia Youssov Sylvie Burnouf Jean-Philippe Azulay Christophe Verny Clarisse Scherer Christine Tranchant Cyril Goizet Sabrina Debruxelles Luc Defebvre Bernard Sablonnière Monique Romon-Rousseaux Luc Buée Alain Destée Olivier Godefroy Alexandra Dürr Bernhard Landwehrmeyer Anne-Catherine Bachoud-Levi Florence Richard David Blum Pierre Krystkowiak Association between caffeine intake and age at onset in Huntington's disease Neurobiology of Disease Huntington's disease Caffeine Adenosine receptors |
author_facet |
Clémence Simonin Cécile Duru Julia Salleron Pascale Hincker Perrine Charles Arnaud Delval Katia Youssov Sylvie Burnouf Jean-Philippe Azulay Christophe Verny Clarisse Scherer Christine Tranchant Cyril Goizet Sabrina Debruxelles Luc Defebvre Bernard Sablonnière Monique Romon-Rousseaux Luc Buée Alain Destée Olivier Godefroy Alexandra Dürr Bernhard Landwehrmeyer Anne-Catherine Bachoud-Levi Florence Richard David Blum Pierre Krystkowiak |
author_sort |
Clémence Simonin |
title |
Association between caffeine intake and age at onset in Huntington's disease |
title_short |
Association between caffeine intake and age at onset in Huntington's disease |
title_full |
Association between caffeine intake and age at onset in Huntington's disease |
title_fullStr |
Association between caffeine intake and age at onset in Huntington's disease |
title_full_unstemmed |
Association between caffeine intake and age at onset in Huntington's disease |
title_sort |
association between caffeine intake and age at onset in huntington's disease |
publisher |
Elsevier |
series |
Neurobiology of Disease |
issn |
1095-953X |
publishDate |
2013-10-01 |
description |
Habitual consumption of caffeine, a non-selective adenosine receptor (AR) antagonist, has been suggested to be beneficial in Parkinson's and Alzheimer's diseases. Experimental evidence support that ARs play a role in Huntington's disease (HD) raising the hypothesis that caffeine may be a life-style modifier in HD. To determine a possible relationship between caffeine consumption and age at onset (AAO) in HD, we retrospectively assessed caffeine consumption in 80 HD patients using a dietary survey and determined relationship with AAO. Following adjustment for gender, smoking status and CAG repeat length, caffeine consumption greater than 190 mg/day was significantly associated with an earlier AAO. These data support an association between habitual caffeine intake and AAO in HD patients, but further studies are warranted to understand the link between these variables. |
topic |
Huntington's disease Caffeine Adenosine receptors |
url |
http://www.sciencedirect.com/science/article/pii/S0969996113001551 |
work_keys_str_mv |
AT clemencesimonin associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT cecileduru associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT juliasalleron associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT pascalehincker associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT perrinecharles associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT arnauddelval associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT katiayoussov associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT sylvieburnouf associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT jeanphilippeazulay associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT christopheverny associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT clarissescherer associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT christinetranchant associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT cyrilgoizet associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT sabrinadebruxelles associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT lucdefebvre associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT bernardsablonniere associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT moniqueromonrousseaux associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT lucbuee associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT alaindestee associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT oliviergodefroy associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT alexandradurr associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT bernhardlandwehrmeyer associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT annecatherinebachoudlevi associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT florencerichard associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT davidblum associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease AT pierrekrystkowiak associationbetweencaffeineintakeandageatonsetinhuntingtonsdisease |
_version_ |
1724208392849850368 |
spelling |
doaj-c66d747e16594f4389dca9b322499c972021-03-22T12:40:01ZengElsevierNeurobiology of Disease1095-953X2013-10-0158179182Association between caffeine intake and age at onset in Huntington's diseaseClémence Simonin0Cécile Duru1Julia Salleron2Pascale Hincker3Perrine Charles4Arnaud Delval5Katia Youssov6Sylvie Burnouf7Jean-Philippe Azulay8Christophe Verny9Clarisse Scherer10Christine Tranchant11Cyril Goizet12Sabrina Debruxelles13Luc Defebvre14Bernard Sablonnière15Monique Romon-Rousseaux16Luc Buée17Alain Destée18Olivier Godefroy19Alexandra Dürr20Bernhard Landwehrmeyer21Anne-Catherine Bachoud-Levi22Florence Richard23David Blum24Pierre Krystkowiak25Department of Neurology and Movement Disorders, Roger Salengro University Hospital, Lille, France; Inserm UMR837, “Evènements moléculaires associés aux stades précoces de la maladie de Parkinson”, Lille, France; Lille-Nord de France University Hospital, University Lille 2/Law & Health, Jean-Pierre Aubert Research Centre, IFR114, IMPRT, Lille, France; Correspondence to: C. Simonin, Service de Neurologie A, Hôpital Salengro, 59037 Lille cedex, France. Fax: +33 320446680.Department of Clinical Neurophysiology, Amiens University Hospital, Amiens, France; Department of Neurology, Amiens University Hospital, Amiens, France; EA 4559, UPJV, Amiens, FranceDepartment of Biostatistics, Lille Nord de France University Hospital, EA 2694 Lille, FranceDepartment of Nutrition, Lille Nord de France University Hospital, Lille, FranceDepartment of Genetics and Cytogenetics, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; AP-HP, Centre de référence maladie rare/maladie de Huntington, Créteil, Paris, FranceDepartment of Neurology and movement disorders, Roger Salengro University Hospital, EA 4559, University Lille 2/Law & Health, Lille Nord de France University Hospital, Lille, FranceAP-HP, Centre de référence maladie rare/maladie de Huntington, Créteil, Paris, FranceInserm UMR837, “Alzheimer & Tauopathies”, Lille, France; Lille-Nord de France University, CHRU-Lille, USDL, Faculté de Médecine, Jean-Pierre Aubert Research Center, IMPRT, Lille, FranceDepartment of Clinical Neurosciences, Movement disorders unit, la Timone University Hospital, Marseille, FranceCentre de référence maladies rares/neurogénétiques, Department of Neurology, Angers University Hospital, Angers, France; UMR Cnrs 6214, UMR Inserm U771, Angers, FranceCentre de référence maladies rares/neurogénétiques, Department of Neurology, Angers University Hospital, Angers, FranceDepartment of neurology, Strasbourg University Hospital, Strasbourg, FranceLaboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA4576, and Department of Medical Genetics, Pellegrin Hospital, Bordeaux University Hospital, Bordeaux, FranceLaboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA4576, and Department of Medical Genetics, Pellegrin Hospital, Bordeaux University Hospital, Bordeaux, FranceDepartment of Neurology and Movement Disorders, Roger Salengro University Hospital, Lille, FranceInserm UMR837, “Alzheimer & Tauopathies”, Lille, France; Lille-Nord de France University, CHRU-Lille, USDL, Faculté de Médecine, Jean-Pierre Aubert Research Center, IMPRT, Lille, France; UF Neurobiologie, Centre de Biologie-pathologie, Lille University Hospital, FranceDepartment of Nutrition, Lille Nord de France University Hospital, Lille, FranceInserm UMR837, “Alzheimer & Tauopathies”, Lille, France; Lille-Nord de France University, CHRU-Lille, USDL, Faculté de Médecine, Jean-Pierre Aubert Research Center, IMPRT, Lille, FranceDepartment of Neurology and Movement Disorders, Roger Salengro University Hospital, Lille, France; Inserm UMR837, “Evènements moléculaires associés aux stades précoces de la maladie de Parkinson”, Lille, France; Lille-Nord de France University Hospital, University Lille 2/Law & Health, Jean-Pierre Aubert Research Centre, IFR114, IMPRT, Lille, FranceDepartment of Neurology, Amiens University Hospital, Amiens, France; EA 4559, UPJV, Amiens, FranceDepartment of Genetics and Cytogenetics, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; AP-HP, Centre de référence maladie rare/maladie de Huntington, Créteil, Paris, FranceDepartment of Neurology, University of Ulm, Ulm, GermanyAP-HP, Centre de référence maladie rare/maladie de Huntington, Créteil, Paris, FranceUnité d'épidémiologie, Pôle de Santé Publique, Lille Nord de France University Hospital, France; Inserm U744, Lille, France; Institut Pasteur de Lille, Lille, FranceInserm UMR837, “Alzheimer & Tauopathies”, Lille, France; Lille-Nord de France University, CHRU-Lille, USDL, Faculté de Médecine, Jean-Pierre Aubert Research Center, IMPRT, Lille, France; Correspondence to: D. Blum, Inserm UMR837, Place de Verdun, 59045, Lille Cedex, France. Fax: +33 320538562.Department of Neurology, Amiens University Hospital, Amiens, France; EA 4559, UPJV, Amiens, France; Correspondence to: P. Krystkowiak, Service de Neurologie, CHU d'Amiens, 80054 Amiens Cedex, France. Fax: +33 22668244.Habitual consumption of caffeine, a non-selective adenosine receptor (AR) antagonist, has been suggested to be beneficial in Parkinson's and Alzheimer's diseases. Experimental evidence support that ARs play a role in Huntington's disease (HD) raising the hypothesis that caffeine may be a life-style modifier in HD. To determine a possible relationship between caffeine consumption and age at onset (AAO) in HD, we retrospectively assessed caffeine consumption in 80 HD patients using a dietary survey and determined relationship with AAO. Following adjustment for gender, smoking status and CAG repeat length, caffeine consumption greater than 190 mg/day was significantly associated with an earlier AAO. These data support an association between habitual caffeine intake and AAO in HD patients, but further studies are warranted to understand the link between these variables.http://www.sciencedirect.com/science/article/pii/S0969996113001551Huntington's diseaseCaffeineAdenosine receptors |